Novel oral therapy for the treatment of iron deficiency anaemia (IDA)

Specialty pharmaceutical company focused on the development and commercialisation of mineral-derived, late-stage, hospital-focused pharmaceuticals that address areas of high unmet medical need.

 Lead product ST10

ST10 is a novel oral ferric iron therapy for the treatment of iron deficiency that is an effective alternative to parenteral (IV) iron in ferrous intolerant patients. GI absorption of ST10 is at least as good as ferrous products at a significantly lower daily dose and it is not affected by gastric pH, so it can be co-prescribed with widely used acid-reducers.

Shield received CHMP positive opinion for Feraccru® (Ferric Maltol) for the treatment of Iron Deficiency in adults.

 Additional product PT20

PT20 is a novel iron-based phosphate binder that we are developing for the treatment of hyperphosphatemia.

Robust clinical results

Strongly positive phase 3 data for ST10 clearly indicates that it is an effective oral treatment for IDA in inflammatory bowel disease (IBD) and chronic kidney disease (CKD). These patients are currently dependent on IV iron as they are unable to tolerate existing oral products. Given that existing oral iron products have substantial side effects not observed with ST10 it also has the potential to be used across a wide range of indications where iron deficiency is frequently seen.


Company has successfully listed on London Stock Exchange.